Skip to main content

Table 1 Patient characteristics

From: Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models

 

Main population (n = 1974)

Sub-analyses 1 (n = 1543)

Sub-analyses 2 (n = 2617)

Sub-analyses 3 (n = 1991)

Follow-up time in years, median (IQR)

5 (2.6,9.1)

5 (2.7,10.3)

5 (2.3,7.7)

5 (2.5,8.5)

Age in years, median (IQR)

52.0 (43.7,59.4)

53.1 (45,60.5)

54 (45.5,61)

55.3 (46.8,62)

Females, n (%)

1465 (74%)

1095 (71%)

1955 (75%)

1432 (72%)

Disease duration in years, median (IQR)

0.6 (0.1,5.8)

0.4 (0,4.3)

0.8 (0.1,7.6)

0.6 (0.1,6)

Rheumatoid factor, n (%)

1437 (73%)

1078 (70%)

1907 (74%)

1392 (70%)

Anti-cyclic citrullinated peptide antibody, n (%)

1239 (66%)

905 (62%)

1649 (67%)

1177 (63%)

Glucocorticosteroids, n (%)

469 (24%)

345 (22%)

675 (26%)

502 (25%)

Biologic DMARD, n (%)

193 (10%)

149 (10%)

321 (12%)

239 (12%)

Synthetic DMARD, n (%)

722 (38%)

517 (34%)

1056 (43%)

743 (37%)

Methotrexate, n (%)

581 (30%)

365 (24%)

864 (34%)

529 (27%)

DAS 28, mean (SD)

4.2 (1.6)

4.3 (1.5)

4.1 (1.6)

4.2 (1.5)

 Remission (< 2.6)

334 (18%)

206 (14%)

491 (20%)

280 (15%)

 Low disease activity (2.6, 3.2)

169 (9%)

141 (10%)

234 (9%)

187 (10%)

 Moderate disease activity (3.2, 5.1)

810 (43%)

681 (47%)

1051 (42%)

876 (47%)

 High disease activity (> 5.1)

566 (30%)

433 (30%)

704 (28%)

540 (29%)

CRP (mg/l), median (IQR)

6.2 (1.4, 18)

8 (2, 21)

6.2 (1.4, 17)

8 (2, 20)

ESR (mm/h), median (IQR)

20 (10, 35.9)

20 (10, 36)

20 (10, 36)

20 (10, 36)

TJC 28, median (IQR)

4 (1, 8)

4 (2, 8)

4 (1, 8)

4 (1, 8)

SJC 28, median (IQR)

5 (2, 9)

5 (2, 9)

4 (1, 9)

5 (2, 9)

Total cholesterol (mmol/l), median (IQR)

5.2 (4.4, 5.9)

5.3 (4.5, 6.1)

5.2 (4.4, 6)

5.4 (4.6, 6.1)

HDL-c (mmol/l), median (IQR)

1.4 (1.1, 1.7)

1.4 (1.2, 1.7)

1.4 (1.1, 1.7)

1.4 (1.2, 1.7)

LDL-c (mmol/l), median (IQR)

3.1 (2.4, 3.8)

3.2 (2.6, 4)

3.1 (2.4, 3.8)

3.2 (2.6, 3.9)

Triglyceride (mmol/l), median (IQR)

1.2 (0.9, 1.7)

1.2 (0.9, 1.7)

1.2 (0.9, 1.7)

1.2 (0.9, 1.7)

Systolic BP (mm Hg), mean (SD)

134.1 (21.4)

137.7 (21.2)

136.1 (21.8)

139.7 (21.7)

Diastolic BP (mm Hg), mean (SD)

80.1 (10.8)

81.4 (10.5)

80.8 (11)

82.2 (10.7)

BMI (kg/m2), median (IQR)

25.6 (23.0, 28.7)

25.4 (22.9, 28.4)

26.1 (23.4, 29.5)

25.9 (23.3, 29.3)

BMI ≥ 30 kg/m2, n (%)

324 (19%)

226 (17%)

523 (23%)

366 (22%)

Current smokers, n (%)

560 (30%)

497 (34%)

678 (28%)

599 (32%)

  1. IQR inter-quartile range, SD standard deviation, bDMARDs and sDMARDs biologic and synthetic disease-modifying antirheumatic drugs, DAS28 disease activity score using 28 joint count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HDL-c high-density lipoprotein cholesterol, sBP and dBP systolic and diastolic blood pressure. Baseline characteristics describing demographic data, rheumatoid arthritis-related disease characteristics, and cardiovascular risk factors in rheumatoid arthritis at baseline. Data are also specified on patients who do and do not experience CVD events during follow-up. In subanalyses 1, only European rheumatoid arthritis cohorts were included. In subanalyses 2, rheumatoid arthritis patients on lipid-lowering therapy and/or antihypertensive treatment were included. In subanalyses 3, analyses were performed on patients from European rheumatoid arthritis cohorts also including patients on lipid-lowering therapy and/or antihypertensive treatment
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us